[HTML][HTML] Therapeutic advances in multiple sclerosis
JH Yang, T Rempe, N Whitmire, A Dunn-Pirio… - Frontiers in …, 2022 - frontiersin.org
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that
causes significant disability and healthcare burden. The treatment of MS has evolved over …
causes significant disability and healthcare burden. The treatment of MS has evolved over …
[HTML][HTML] Early aggressive treatment approaches for multiple sclerosis
A Simpson, EM Mowry, SD Newsome - Current treatment options in …, 2021 - Springer
Purpose of review This review presents a comprehensive analysis of the current high-
efficacy disease-modifying therapies (DMTs) available for treatment of multiple sclerosis …
efficacy disease-modifying therapies (DMTs) available for treatment of multiple sclerosis …
How patients with multiple sclerosis acquire disability
Patients with multiple sclerosis acquire disability either through relapse-associated
worsening (RAW) or progression independent of relapse activity (PIRA). This study …
worsening (RAW) or progression independent of relapse activity (PIRA). This study …
[HTML][HTML] Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated …
B Sharrack, R Saccardi, T Alexander… - Bone marrow …, 2020 - nature.com
These updated EBMT guidelines review the clinical evidence, registry activity and
mechanisms of action of haematopoietic stem cell transplantation (HSCT) in multiple …
mechanisms of action of haematopoietic stem cell transplantation (HSCT) in multiple …
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
F Piehl - Journal of Internal Medicine, 2021 - Wiley Online Library
The treatment of multiple sclerosis (MS), the most common chronic inflammatory,
demyelinating and neurodegenerative disease of the central nervous system (CNS) …
demyelinating and neurodegenerative disease of the central nervous system (CNS) …
[HTML][HTML] Immunological aspects of approved MS therapeutics
Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading
to disability in young adults. The outcome of the disease is unpredictable, and over time …
to disability in young adults. The outcome of the disease is unpredictable, and over time …
[HTML][HTML] Roles of sphingosine-1-phosphate signaling in cancer
P Wang, Y Yuan, W Lin, H Zhong, K Xu, X Qi - Cancer cell international, 2019 - Springer
The potent pleiotropic lipid mediator sphingosine-1-phosphate (S1P) participates in
numerous cellular processes, including angiogenesis and cell survival, proliferation, and …
numerous cellular processes, including angiogenesis and cell survival, proliferation, and …
Treatment optimization in multiple sclerosis: Canadian MS working group recommendations
MS Freedman, V Devonshire, P Duquette… - Canadian Journal of …, 2020 - cambridge.org
The Canadian Multiple Sclerosis Working Group has updated its treatment optimization
recommendations (TORs) on the optimal use of disease-modifying therapies for patients …
recommendations (TORs) on the optimal use of disease-modifying therapies for patients …
Sphingosine 1-phosphate receptor modulators for multiple sclerosis
R Roy, AA Alotaibi, MS Freedman - CNS drugs, 2021 - Springer
Fingolimod (Gilenya) received regulatory approval from the US FDA in 2010 as the first-in-
class sphingosine 1-phosphate (S1P) receptor (S1PR) modulator and was the first oral …
class sphingosine 1-phosphate (S1P) receptor (S1PR) modulator and was the first oral …
[HTML][HTML] Multiple sclerosis in children: differential diagnosis, prognosis, and disease-modifying treatment
D Jakimovski, S Awan, SP Eckert, O Farooq… - CNS drugs, 2022 - Springer
Pediatric-onset multiple sclerosis (POMS) is a rare neuroinflammatory and
neurodegenerative disease that has a significant impact on long-term physical and cognitive …
neurodegenerative disease that has a significant impact on long-term physical and cognitive …